Wockhardt in-licenses UK firm's leucoderma drug

Wockhardt has in-licenced a dermatology drug from UK-based LSI.

According to an official release issued to the BSE today, as per the terms of the agreement, Wockhardt will manufacture and market Vitix, a patented product for the treatment of vitiligo - the skin pigmentation disorder commonly known as leucoderma.

Vitix, a gel for topical application, will be manufactured by Wockhardt in India from active pharmaceutical ingredients (API) imported from LSI. The product is expected to be launched in the last quarter of 2006.

"This agreement is part of Wockhardt's initiative to bring new advances in medicine to India...we plan to expand our portfolio in cardiology, diabetology and dermatology by introducing new products that have proved their effectiveness in other parts of the world," Habil Khorakiwala, chairman of Wockhardt, said.